Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker L et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.

Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
Moreau P et al. Br J Haematol. 2014 Sep 19. doi: 10.1111/bjh.13128. [Epub ahead of print].

Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma – response to Moreau et al.
Leiba M et al. Br J Haematol. 2014 Sep 24. doi: 10.1111/bjh.13125. [Epub ahead of print].

Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium.
Selleslag D et al. Acta Clin Belg. 2014 Sep 18:2295333714Y0000000077. [Epub ahead of print].

Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
Sánchez-Ortega I et al. Bone Marrow Transplant. 2014 Sep 15. doi: 10.1038/bmt.2014.196. [Epub ahead of print].

Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A et al. N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888.

Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study.
Byrne M et al. Clin Med Insights Oncol. 2014 Sep 3;8:101-5. doi: 10.4137/CMO.S16835. eCollection 2014.

Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Kuroda J et al. Ann Hematol. 2014 Sep 12. [Epub ahead of print].

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Dimopoulos MA et al. Haematologica. 2014 Sep 26. pii: haematol.2014.112037. [Epub ahead of print].

Pomalidomide for the management of refractory multiple myeloma.
Summers BB et al. Am J Health Syst Pharm. 2014 Sep 1;71(17):1443-1448.